BioTuesdays

Tag - CLR 131

Cellectar Biosciences
Markets

Roth starts Cellectar Biosciences at buy; PT $11

Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted...

September 13, 2019
Cellectar Biosciences
Markets

Brookline starts Cellectar Biosciences at buy; PT $6

Brookline Capital Markets launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and price target of $6. The stock closed at $2.14 on July 29. Cellectar has a unique cancer target delivery platform...

July 30, 2019